Skip to main content
SpringerLink
Log in

HLA Class-I Expression and Cancer Immunotherapy

  • Chapter
  • First Online:
MHC Class-I Loss and Cancer Immune Escape

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 1151))

Abstract

The impact of HLA class I loss in cancer immunotherapy is carefully analyzed. Why some metastatic lesions regress and other progress after immunotherapy? Are T lymphocytes responsible for tumour rejection and how these responses can be boosted? These questions are discussed in the context of the molecular mechanisms responsible for MHC/HLA class I alterations. If the metastatic tumour cells harbor “irreversible/hard” HLA lesions, they will escape and kill the host. In contrast, if the molecular lesion is “reversible/soft”, tumor cells can potentially recover HLA-class I expression and can finally be destroyed. These important new concepts are integrated together and gain a great importance in the new era of “immune checkpoint antibodies”. Finally, the ability to recover HLA-I expression in tumours harboring “structural-irreversible-hard” genetic lesions is seen as a challenge for the future investigation.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Abril E, Real LM, Serrano A, Jimenez P, Garcia A, Canton J, Trigo I, Garrido F, Ruiz-Cabello F (1998) Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line. Cancer Immunol Immunother 47:113–120

    Article  CAS  Google Scholar 

  • Andersen R, Donia M, Ellebaek E, Holz Borch T, Kongsted P, Iversen TZ, Rosenkrantz Hölmich L, Westergren Hendel H, Met O, Hald AM, Thor Straten P, Svane IM (2016) Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL-2 regimen. Clin Cancer Res 22(15):3734–3745

    Article  CAS  Google Scholar 

  • Angell TE, Lechner MG, Jang JK, LoPresti JS, Epstein AL (2014) MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro. Clin Cancer Res 20:6034–6044

    Article  CAS  Google Scholar 

  • Aptsiauri N, Carretero R, Garcia-Lora A, Real LM, Cabrera T, Garrido F (2008) Regressing and progressing metastatic lesions: Resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother 57:1727–1733

    Article  CAS  Google Scholar 

  • Aptsiauri N, Garcia-Lora A, Garrido F (2014) Chapter 5: “Hard” and “Soft” loss of MHC class I expression in cancer cells. In: Rees B (ed) Tumour immunology & immunotherapy. Oxford University Press, pp 63–78

    Google Scholar 

  • Benitez R, Godelaine D, Lopez-Nevot MA, Brasseur F, Jimenez P, Marchand M, Oliva MR, van Baren N, Cabrera T, Andry G, Landry C, Ruiz-Cabello F, Boon T, Garrido F (1998) Mutations of the β2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens 52:520–529

    Article  CAS  Google Scholar 

  • Bernal M, Ruiz-Cabello F, Concha A, Paschen A, Garrido F (2012) Implication of the β2 microglobuline gene in the generation of tumour escape phenotypes. Cancer Immunol Immunother 61(9):1359–1371

    Article  Google Scholar 

  • Cabrera T, Maleno I, Collado A, Lopez-Nevot MA, Tait B, Garrido F (2007) Analysis of HLA class I alterations in tumours: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens 69(Suppl 1):264–268

    Article  CAS  Google Scholar 

  • Carretero R, Romero JM, Ruiz-Cabello F, Maleno I, Rodriguez F, Camacho FM, Real LM, Garrido F, Cabrera T (2008) Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics 60:439–447

    Article  CAS  Google Scholar 

  • Carretero R, Cabrera T, Sáenz-López P, Maleno I, Aptsiauri N, Cózar JM, Garrido F (2011) Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells. Int J Cancer 129(4):839–846

    Article  CAS  Google Scholar 

  • Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, Liu H, Camacho F, Marincola FM, Garrido F, Cabrera T (2012) Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 131:387–395

    Article  CAS  Google Scholar 

  • Carretero FJ, Del Campo AB, Zinchenko S, Garrido F, Aptsiauri N (2017) Recovery HLA-A2 and β2-microglobulin expression in tumor cells using viral vectors. J Cancer Sci Ther 9:622–629

    CAS  Google Scholar 

  • Chang CC, Campoli M, Restifo NP, Wang X, Ferrone S (2005) Immune selection of hot-spot β2 microglobuline gene mutations, HLA-A2 alloespecificity loss and antigen processing machinery component down-regulation in melanoma cells derived from recurrent metastasis following immunotherapy. J Immunol 174:1462–1471

    Article  CAS  Google Scholar 

  • del Campo AB, Aptsiauri N, Méndez R, Zinchenko S, Vales A, Paschen A, Ward S, Ruiz-Cabello F, González-Aseguinolaza G, Garrido F (2009) Efficient recovery of HLA class I expression in human tumor cells after β2-microglobulin gene transfer using adenoviral vector: implicationsfor cancer immunotherapy. Scand J Immunol 70(2):125–135

    Article  Google Scholar 

  • del Campo AB, Carretero J, Aptsiauri N, Garrido F (2012) Targeting HLA class I expression to increase tumor immunogenicity. Tissue Antigens 79(3):147–154

    Article  Google Scholar 

  • del Campo AB, Kyte JA, Carretero J, Zinchencko S, Mendez R, Gonzalez-Aseguinolaza G, Ruiz-Cabello F, Aamdal S, Gaudernac G, Garrido F, Aptsiauri N (2014a) Immune escape of cancer cells with β2 microglobuline loss over the course of metastatic melanoma. Int J Cancer 134(1):102–113

    Article  Google Scholar 

  • del Campo AB, Carretero J, Muñoz JA, Zinchenko S, Ruiz-Cabello, Gonzalez-Aseguinolaza G, Garrido F, Aptsiauri N (2014b) Adenovirus expressing β2 microglobuline recovers HLA class I expression and antitumor immunity by increasing T cell recognition. Cancer Gene Ther 21(8):317–332

    Article  Google Scholar 

  • Feldman M, Eisenbach L (1988) Genes controlling the metastatic phenotype. Cancer Surv 7:555–572

    CAS  PubMed  Google Scholar 

  • Festenstein, Schmidt W (1981) Variation in MHC antigen profile of tumour cells and its biological effect. Immunol Rev 60:85

    Article  CAS  Google Scholar 

  • Festenstein H, Schmidt W, Testorelli C, Marelli O, Simpson S (1980) Biologic effects of the altered MHS profile on the K36 tumor, a spontaneous leukemia of AKR. Transplant Proc 12(1):25–28

    CAS  PubMed  Google Scholar 

  • Garrido F, Festenstein H, Schirrmacher V (1976) Further evidence for derepression of H-2 and Ia-likespecificities of foreign haplotypes in mouse tumour cell lines. Nature 261(5562):705–707

    Article  CAS  Google Scholar 

  • Garrido F, Cabrera T, Aptsiauri N (2010a) “Hard” and “Soft” lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer 127(2):249–256

    CAS  PubMed  Google Scholar 

  • Garrido F, Algarra I, García-Lora AM (2010b) The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harboring structural-irreversible “hard” lesions. Cancer Immunol Immunother 59(10):1601–1606

    Article  CAS  Google Scholar 

  • Garrido C, Romero I, Berruguilla E, Cancela B, Algarra I, Collado A, Garcia-Lora AM, Garrido F (2011) Immunotherapy eradicates metastases with reversible defects in MHC class I expression. Cancer Immunol Immunother 60(9):1257–1268

    Article  CAS  Google Scholar 

  • Garrido F, Aptsiauri N, Doorduijn E, Garcia-Lora A, van Hall T (2016) The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol 39:44–51

    Article  CAS  Google Scholar 

  • Garrido G, Rabasa A, Garrido C, Lisset C, Garrido F, Garcia-Lora A, Sanchez-Ramirez B (2017) Upregulation of HLA class I expression on tumour cells by the anti-EGFR antibody Nimotuzumab. Front Pharmacol. https://doi.org/10.3389/fphar.2017.00595

  • Hammerling G, Klar D, Katzav S, Segal S, Feldman M, Wallich R, Hammerling A (1986) Manipulation of metastasis and tumor growth by transfection with histocompatibility class I genes. J Immunogenet 13:153–157

    Article  CAS  Google Scholar 

  • Hui K, Grosveld F, Festenstein H (1984) Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 311(5988):750–752

    Article  CAS  Google Scholar 

  • Kloor M, Michel S, von Knebel Doeberitz M (2010) Immune evasion of microsatelite unstable colorectal cancers. Int J Cancer 127:1001–1010

    Article  CAS  Google Scholar 

  • Lampen MH, van Hall T (2011) Strategies to counteract MHC-I defects in tumors. Curr Opin Immunol 23:293–298

    Article  CAS  Google Scholar 

  • Leach MF, Krummel DR, Allison JP (1996) Enhancement of anti tumour immunity by CTL-4 blockade. Science 271(5256):1734–1736

    Article  CAS  Google Scholar 

  • Maleno I, Romero JM, Cabrera T, Paco L, Aptsiauri N, Cozar JM, Tallada M, Lopez-Nevot MA, Garrido F (2006) LOH at 6p21.3 region and HLA class I altered phenotypes in bladder carcinomas. Immunogenetics 58:503–510

    Article  CAS  Google Scholar 

  • Maleno I, Aptsiauri N, Cabrera T, Gallego A, Paschen A, Lopez- Nevot MA, Garrido F (2011) Frequent loss of heterozygosity in the β2-microglobulin region of chromosome 15 in primary human tumors. Immunogenetics 63:65–71

    Article  CAS  Google Scholar 

  • Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijch R, Humblet et al (1995) Tumour regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883–889

    Article  CAS  Google Scholar 

  • Marchand M, Van Baren N, Weynan P, Brichard V, Dreno B, Tessier M-H, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich P-Y, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie P, Van Der Bruggen P, Boon T (1999) Tumour regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 89:219–230

    Article  Google Scholar 

  • Mendez R, Ruiz-Cabello F, Jimenez P, Paschen A, Knuth A, Jager E, Traversari C, Schadendorf D, Boon T, Garrido F (2006) Impact of HLA class I alterations in patients undergoing T cell specific immunotherapy. Immunobiology of the human MHC. In: Proceedings of the 13th International Histocompatibility Workshop and Conference (IHWC) 2002, vol 2, IHWG Press, pp 512–514

    Google Scholar 

  • Mialdea MJ, Martin J, Gaforio JJ, Algarra I, Perez M, Gonzalez A, Ljunggren HG, Garrido F (1992) Effect of MHC class I transfection on local tumour growth and metastasis in an H-2 negative clone derived from a chemically induced fibrosarcoma. Int J Cancer 52:153–158

    Article  CAS  Google Scholar 

  • Morales A, Eidinger D, Bruce AW (1976) Intracavitary Bacillus Calmette Guerin in the treatment of superficial bladder tumors. J Urol 116:180–183

    Article  CAS  Google Scholar 

  • Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Shadendorf D (1998) Vaccination of melanoma patients with peptide or tumor lysate-pulsed dendritic cells. Nature (Med) 4:328–332

    Article  CAS  Google Scholar 

  • Nio Y, Shiraishi T, Tsubono M, Morimoto H, Tseng C Imai S, Tobe T (1991) In vitro immunomodulating effect of protein-bound polysaccharide,PSK on peripheral blood, regional nodes and spleen lymphocytes in patients with gastric cancer. Cancer Immunol Immunother 32:335–339

    Article  CAS  Google Scholar 

  • Plaksin D, Gelber C, Feldman M, Eisenbach L (1988) Reversal of the metastatic phenotype in Lewis lung carcinoma cells after transfection with syngeneic H-2Kb gene. Proc Natl Acad Sci U S A 85(12):4463–4467

    Article  CAS  Google Scholar 

  • Porgador A, Brenner E, Vadai M, Feldman M, Eisenbach L (1991) Immunization by gamma-IFN-treated B16-F10.9 melanoma cells protects against metastatic spread of the parental tumor. Int J Cancer Suppl 6:54–60

    Article  CAS  Google Scholar 

  • Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yanelli JR, Rosenberg SA (1996) Loss of functional β2-microglobulin in metastatic melanoma from five patients receiving immunotherapy. J Natl Cancer Inst 88:100–108

    Article  CAS  Google Scholar 

  • Rodriguez T, Mendez R, Del Campo A, Jimenez P, Aptsiauri N, Garrido F, Ruiz-Cabello F (2007) Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines. BMC Cancer 7:34

    Article  Google Scholar 

  • Romero I, Martinez M, Garrido C, Collado A, Algarra I, Garrido F, Garcia-Lora AM (2012) The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells. J Pathol 227(3):367–379

    Article  CAS  Google Scholar 

  • Rosenberg SA, Lotze MT, Muul LM (1987) A progress report on the treatment of 157 patients with advance cáncer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316(15):889–897

    Article  CAS  Google Scholar 

  • Ruiz-Cabello F, Garrido F (1998) HLA and cancer: from research to clinical impact. Immunol Today 19:539–542

    Article  CAS  Google Scholar 

  • Ruiz-Cabello F, Cabrera T, Lopez-Nevot MA, Garrido F (2002) Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. Semin Cancer Biol 12:15–24

    Article  CAS  Google Scholar 

  • Sade-Feldman M, Jiao Y, Chen J, Rooney M, Barzily-Rokni M, Eliane JP, Bjorgaard S, Hammond M, Vitzthum H, Blackmon S et al (2017) Resistance to checkpoint blockade therapy throught inactivation of antigen presentation. Nat Commun 8:1136. https://doi.org/10.1038/s41467-017-01062

    Article  PubMed  PubMed Central  Google Scholar 

  • Seliger B, Ruiz-Cabello F, Garrido F (2008) IFN inducibility of major histocompatibility antigens in tumors. Adv Cancer Res 101:249–276

    Article  CAS  Google Scholar 

  • Sharma P, Allison JP (2015) The future of immune checkpoint therapy. Science 348(6230):56–61

    Article  CAS  Google Scholar 

  • Siddle HV, Kreiss A, Tovar C, Yuen CK, Chang Y, Belov K, Swift K, Pearse AM, Hamede R, Jones ME, Skjodt K, Woods GM, Kaufman J (2013) Reversible epigenetic down-regulation of MHC molecules by devil facial tumour disease illustrate immune escape by a contagious cancer. Proc Natl Acad Sci U S A 110(13):5103–5108

    Article  CAS  Google Scholar 

  • Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, Real B, Bielefeld N, Howe S, Weide B, Gutzmer R, Utikal J, Loquai C, Gogas H, Klein-Hitpass L, Zeschnigk M, Westendorf A, Trilling M, Horn S, Schilling B, Schadendorf D, Griewank K, Paschen A (2017) Adquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistance melanoma lesions. Nat Commun 31(8):15440. https://doi.org/10.1038/ncomms15440

    Article  CAS  Google Scholar 

  • Tanaka K, Isselbacher KJ, Khoury G, Jay G (1985) Reversal of oncogenesis by the expression of major histocompatibility complex class I gene. Science 228:26–30

    Article  CAS  Google Scholar 

  • Tanaka K, Hayashi H, Hamada C, Khoury G, Jay G (1986) Expression of major histocompatibility complex class-I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc Natl Acad Sci (Was) 83:8723–8727

    Article  CAS  Google Scholar 

  • Tanaka K, Gorelik E, Watanabe M, Hozumi N, Jay G (1988) Rejection of B16 melanoma induced by expression of a transfected major histocompatibility complex class-I gene. Mol Cell Biol 8:1857–1861

    Article  CAS  Google Scholar 

  • Thor Straten P, Garrido F (2016) Targetless T cells in cancer immunotherapy. J Immunother Cancer 19(4):23–26

    Article  Google Scholar 

  • Tsukagoshi S, Hashimoto Y, Fujii G, Kobayashi H, Nomoto K, Orita K (1984) PSK. Cancer Treat Rew 11:131–139

    Google Scholar 

  • Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M (1985) Abrogation of metastasis properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 315:301–307

    Article  CAS  Google Scholar 

  • Wang E, Worschech A, Marincola FM (2008) The immunological constant of rejection. Trends Immunol 29:256–262

    Article  Google Scholar 

  • Woods GM, Howson LJ, Brown GK, Tovar C, Kreiss A, Corcoran LM, Lyons AB (2015) Immunology of a transmissible cancer spreading among Tasmanian Devils. J Immunol 195:23–29

    Article  CAS  Google Scholar 

  • Yoshihama S, Roszik J, Downs I, Meissner T, Vijayan S, Chapuy B, Sidiq T, Shipp M, Lizee G, Kobayashi K (2016) NLRC5/MHC class I transactivator is a target for immune evasión in cancer. PNAS 113:5999–6004

    Article  CAS  Google Scholar 

  • Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY, Abril-Rodriguez G, Sandoval S, Barthly et al (2016) Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 375:819–829

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Departamento de Analisis Clinicos e Inmunologia, Hospital Universitario Virgen de las Nieves, Facultad de Medicina, Universidad de Granada, Granada, Spain

    Federico Garrido

Authors
  1. Federico Garrido
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Garrido, F. (2019). HLA Class-I Expression and Cancer Immunotherapy. In: MHC Class-I Loss and Cancer Immune Escape. Advances in Experimental Medicine and Biology, vol 1151. Springer, Cham. https://doi.org/10.1007/978-3-030-17864-2_3

Download citation

Publish with us

Policies and ethics

Search

Navigation